Tonix Pharmaceuticals Holding (TNXP) Receivables - Other (2022 - 2026)

Tonix Pharmaceuticals Holding's Receivables - Other history runs 5 years deep, the most recent figure standing at $3.4 million for Q1 2026.

• On a quarterly basis, Receivables - Other rose 162.99% year-over-year to $3.4 million in Q1 2026; TTM through Mar 2026 was $3.4 million, a 162.99% increase from a year earlier, with the FY2025 full-year figure at $3.5 million, up 265.69% from the prior year.
• Receivables - Other slipped to $3.4 million in Q1 2026 per TNXP's latest filing, from $3.5 million in the prior quarter.
• Across five years, Receivables - Other topped out at $8.0 million in Q4 2022 and bottomed at $953000.0 in Q4 2024.
• The 5-year median for Receivables - Other is $2.1 million (2024), against an average of $2.9 million.
• Across the five-year window, Receivables - Other slumped 79.24% in 2024 and jumped 265.69% in 2025, its largest moves.
• Year by year, Receivables - Other stood at $8.0 million in 2022, then tumbled by 42.93% to $4.6 million in 2023, then slumped by 79.24% to $953000.0 in 2024, then soared by 265.69% to $3.5 million in 2025, then dropped by 2.73% to $3.4 million in 2026.
• Per Business Quant, the three latest TNXP Receivables - Other figures stand at $3.4 million (Q1 2026), $3.5 million (Q4 2025), and $1.7 million (Q3 2025).